GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
Crossref DOI link: https://doi.org/10.1186/s13063-017-2107-0
Published Online: 2017-07-26
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Oughton, Jamie B.
Collett, Laura
Howard, Dena R.
Hockaday, Anna
Munir, Talha
McMahon, Kathryn
McParland, Lucy
Dimbleby, Claire
Phillips, David
Rawstron, Andy C.
Hillmen, Peter
Funding for this research was provided by:
Cancer Research UK (C18027/A13762)
Roche (ML29281)